BACKGROUND:Necator americanusAncylostoma-secreted protein 2 (Na-ASP-2) is secreted by infective hookworm larvae on entry into human hosts. Vaccination of laboratory animals with recombinant Na-ASP-2 provides significant protection against challenge infections. In endemic areas antibodies to Na-ASP-2 are associated with reduced risk of heavy N americanus infections. OBJECTIVE: To assess the safety and immunogenicity of recombinant Na-ASP-2 adjuvanted with Alhydrogel in healthy Brazilian adults previously infected with N americanus. METHODS: Participants were randomized to receive Na-ASP-2 or hepatitis B vaccine. Major IgG and IgE epitopes of the Na-ASP-2 molecule were mapped by using sera from these same subjects. Seroepidemiologic studies in adults and children residing in hookworm-endemic areas were conducted to assess the prevalence of IgE responses to Na-ASP-2. RESULTS: Vaccination with a single dose of Na-ASP-2 resulted in generalized urticarial reactions in several volunteers. These reactions were associated with pre-existing Na-ASP-2-specific IgE likely induced by previous hookworm infection. Surveys revealed that a significant proportion of the population in hookworm-endemic areas had increased levels of IgE to Na-ASP-2. Epitope mapping demonstrated sites on the Na-ASP-2 molecule that are uniquely or jointly recognized by IgG and IgE antibodies. CONCLUSION: Infection with N americanus induces increased levels of total and specific IgE to Na-ASP-2 that result in generalized urticaria on vaccination with recombinant Na-ASP-2. These data advance knowledge of vaccine development for helminths given their propensity to induce strong T(H)2 responses. Study data highlight the important differences between the immune responses to natural helminth infection and to vaccination with a recombinant helminth antigen.
RCT Entities:
BACKGROUND:Necator americanusAncylostoma-secreted protein 2 (Na-ASP-2) is secreted by infective hookworm larvae on entry into human hosts. Vaccination of laboratory animals with recombinant Na-ASP-2 provides significant protection against challenge infections. In endemic areas antibodies to Na-ASP-2 are associated with reduced risk of heavy N americanus infections. OBJECTIVE: To assess the safety and immunogenicity of recombinant Na-ASP-2 adjuvanted with Alhydrogel in healthy Brazilian adults previously infected with N americanus. METHODS:Participants were randomized to receive Na-ASP-2 or hepatitis B vaccine. Major IgG and IgE epitopes of the Na-ASP-2 molecule were mapped by using sera from these same subjects. Seroepidemiologic studies in adults and children residing in hookworm-endemic areas were conducted to assess the prevalence of IgE responses to Na-ASP-2. RESULTS: Vaccination with a single dose of Na-ASP-2 resulted in generalized urticarial reactions in several volunteers. These reactions were associated with pre-existing Na-ASP-2-specific IgE likely induced by previous hookworm infection. Surveys revealed that a significant proportion of the population in hookworm-endemic areas had increased levels of IgE to Na-ASP-2. Epitope mapping demonstrated sites on the Na-ASP-2 molecule that are uniquely or jointly recognized by IgG and IgE antibodies. CONCLUSION:Infection with N americanus induces increased levels of total and specific IgE to Na-ASP-2 that result in generalized urticaria on vaccination with recombinant Na-ASP-2. These data advance knowledge of vaccine development for helminths given their propensity to induce strong T(H)2 responses. Study data highlight the important differences between the immune responses to natural helminth infection and to vaccination with a recombinant helminth antigen.
Authors: Brent Schneider; Amar R Jariwala; Maria Victoria Periago; Maria Flávia Gazzinelli; Swaroop N Bose; Peter J Hotez; David J Diemert; Jeffrey M Bethony Journal: Hum Vaccin Date: 2011-11-01
Authors: Rahul Tyagi; Anja Joachim; Bärbel Ruttkowski; Bruce A Rosa; John C Martin; Kymberlie Hallsworth-Pepin; Xu Zhang; Philip Ozersky; Richard K Wilson; Shoba Ranganathan; Paul W Sternberg; Robin B Gasser; Makedonka Mitreva Journal: Biotechnol Adv Date: 2015-05-27 Impact factor: 14.227
Authors: Luis Caraballo; Josefina Zakzuk; Bee Wah Lee; Nathalie Acevedo; Jian Yi Soh; Mario Sánchez-Borges; Elham Hossny; Elizabeth García; Nelson Rosario; Ignacio Ansotegui; Leonardo Puerta; Jorge Sánchez; Victoria Cardona Journal: World Allergy Organ J Date: 2016-06-27 Impact factor: 4.084
Authors: Javier Sotillo; Alejandro Sanchez-Flores; Cinzia Cantacessi; Yvonne Harcus; Darren Pickering; Tiffany Bouchery; Mali Camberis; Shiau-Choot Tang; Paul Giacomin; Jason Mulvenna; Makedonka Mitreva; Matthew Berriman; Graham LeGros; Rick M Maizels; Alex Loukas Journal: Mol Cell Proteomics Date: 2014-07-03 Impact factor: 5.911
Authors: Nina Salinger Prasanphanich; Anthony E Luyai; Xuezheng Song; Jamie Heimburg-Molinaro; Msano Mandalasi; Megan Mickum; David F Smith; A Kwame Nyame; Richard D Cummings Journal: Glycobiology Date: 2014-04-11 Impact factor: 4.313
Authors: Hannah W Wu; Sangshin Park; Sunthorn Pond-Tor; Ron Stuart; Sha Zhou; Yang Hong; Amanda E Ruiz; Luz Acosta; Blanca Jarilla; Jennifer F Friedman; Mario Jiz; Jonathan D Kurtis Journal: J Infect Dis Date: 2021-04-08 Impact factor: 5.226